Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 3/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299550 | 0.94 | NAAA (0.56) | NAAAALDH1A1MMP12MMP2MMP1 | |
| SCHEMBL2918702 | 0.85 | GAA (0.64) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL13684290 | 0.84 | NAAA (0.51) | NAAASMN1; SMN2MMP12MMP2MMP1 | |
| SCHEMBL12898184 | 0.83 | NAAA (0.54) | NAAAALDH1A1MMP12MMP2MMP1 | |
| SCHEMBL11690233 | 0.82 | MMP12 (0.44) | NAAAALDH1A1SMN1; SMN2GAACYP1A2 | |
| SCHEMBL24062797 | 0.81 | NAAA (0.52) | NAAAALDH1A1MMP12MMP2MMP1 | |
| SCHEMBL22699958 | 0.81 | ALDH1A1 (0.52) | NAAAALDH1A1SMN1; SMN2GAAMMP12 | |
| SCHEMBL12885293 | 0.79 | GAA (0.53) | ALDH1A1SMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL28861927 | 0.79 | NPC1 (0.51) | NAAAALDH1A1SMN1; SMN2MMP12MMP2 | |
| SCHEMBL5931094 | 0.78 | EGFR (0.55) | ALDH1A1GAALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067440-B2 | Phosphonium salts derivatives and uses thereof | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2011-11-29 | — | — | US | disclosed |
| US-20110092683-A1 | PHOSPHONIUM SALTS DERIVATIVES AND USES THEREOF | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092683-A1 | PHOSPHONIUM SALTS DERIVATIVES AND USES THEREOF | PI4K2A, PIP4K2A, PI4K2B | NAAA 873/4885ALDH1A1 3468/4885SMN1; SMN2 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.